Continuous administration of heparin during free flap surgery for head and neck tumors reduces the risk of pulmonary embolism

在头颈部肿瘤游离皮瓣手术中持续使用肝素可降低肺栓塞的风险。

阅读:1

Abstract

PURPOSE: This study investigated the impact of different anticoagulation protocols on the incidence of pulmonary embolism (PE) in patients with head and neck tumors who underwent microvascular flap reconstruction. METHODS: We conducted a retrospective case‒control analysis of 92 patients. Two anticoagulation strategies were evaluated: one group received 10000 IU of unfractionated heparin (UFH) administered over 24 hours (h) starting 6 h postoperatively for one week.The other group received 3 IU of UFH per kilogram of total body weight per h at the onset of surgery until 6 h after surgery. The activated partial thromboplastin time (aPTT) target was subsequently set at 50 to 60 seconds for one week. RESULTS: The group that received intraoperative UFH presented a significantly lower incidence of PE (6.5% compared with 17.4% in the group that received 10,000 IU of UFH 6 h postoperatively), independent of the type of flap used for reconstruction. This effect was particularly notable in patients who received a forearm flap for reconstruction. There was no statistically significant difference in the incidence of bleeding requiring intervention between the two groups; however, a trend was noted, as postoperative bleeding occurred more frequently in the group receiving intraoperative heparinization. CONCLUSIONS: Our findings suggest that the intraoperative administration of UFH is effective in significantly reducing the risk of PE in patients with head and neck tumors undergoing free flap reconstruction. These results highlight the need for further research to optimize anticoagulation protocols that effectively balance thromboembolic prevention and the risk of bleeding complications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。